Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27814098 | 0.98 | NPSR1 (0.43) | NPSR1NAAACYP19A1CYP17A1EPHX1 | |
| SCHEMBL5608309 | 0.86 | DPP4 (0.43) | NPSR1NAAAALDH1A1DPP4 | |
| SCHEMBL12093413 | 0.84 | NAAA (0.38) | NPSR1NAAACYP19A1CYP17A1EPHX2 | |
| SCHEMBL231596 | 0.82 | NPSR1 (0.56) | NPSR1NAAACYP19A1CYP17A1EPHX2 | |
| SCHEMBL15145523 | 0.82 | NAAA (0.34) | NPSR1NAAACYP19A1CYP17A1EPHX2 | |
| SCHEMBL8395205 | 0.82 | NAAA (0.45) | NPSR1NAAACYP19A1CYP17A1EPHX1 | |
| Hydrochloric Acid SCHEMBL27869489 | 0.81 | NAAA (0.33) | NPSR1NAAACYP19A1CYP17A1EPHX1 | |
| SCHEMBL5607557 | 0.81 | EP300 (0.35) | NPSR1NAAADPP4 | |
| SCHEMBL865315 | 0.80 | NPSR1 (0.48) | NPSR1NAAACYP19A1CYP17A1EPHX1 | |
| SCHEMBL27736443 | 0.80 | CYP19A1 (0.44) | NPSR1NAAACYP19A1CYP17A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14445 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823115-B | Compound for degrading Pol theta based on hydrophobic tag and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026090085-A1 | TREATMENT OF CD33 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| EP-4627082-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250283079-A1 | ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-11 | — | — | US | claimed |
| US-12391945-B2 | Coronavirus IRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4594492-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-12378553-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-6319906-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, FOR INHIBITING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS | 2001-11-20 | — | — | US | claimed |
| US-6312900-B1 | FOR MODULATING METASTASIS OF MALIGNANT TUMORS VIA MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| JP-2000507833-A | — | — | 2000-06-27 | — | — | JP | claimed |
| US-6077833-A | FOR DIAGNOSIS, PREVENTION AND TREATMENT OF IMMUNE STATES AND DISORDERS AMENABLE TO TREATMENT THROUGH MODULATION OF T CELL ACTIVATION SUCH AS FOR PREVENTING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | claimed |
| US-6001991-A | NUCLEOTIDE SEQUENCES WHICH HYBRIDIZE TO AND SUPPRESS EXPRESSION OF MULTIDRUG RESISTANCE GENE; FOR PREVENTING OR MODULATING THE DEVELOPMENT OF MULTIDRUG RESISTANCE DURING CHEMOTHERAPEUTIC TREATMENT OR RESENSITIZING TREATED CELLS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998014615-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF MDR P-GLYCOPROTEIN GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | claimed |
| EP-0358574-B1 | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-02-17 | — | — | EP | claimed |
| US-5015758-A | Process for the preparation of 1-adamantane derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-05-14 | — | — | US | claimed |